Publicacións en colaboración con investigadores/as de AstraZeneca (United Kingdom) (7)

2024

  1. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2021

  1. DUART: Durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

    Future Oncology, Vol. 17, Núm. 34, pp. 4657-4663

  2. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2014

  1. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1656-1663

2011

  1. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

1999

  1. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer

    Annals of Oncology, Vol. 10, Núm. 10, pp. 1219-1225